Roche continues to solidify its position as a leader in oncology with its latest strategic partnership with Hansoh Pharma, aimed at advancing an innovative treatment for colorectal cancer.
The $80 million upfront payment for the global rights to a promising antibody-drug conjugate (ADC) targeting CDH17 highlights both companies’ commitment to addressing unmet needs in cancer therapy.
In this article, we will delve into the details of the collaboration, explore the financial implications, and assess the future prospects of the CDH17 ADC as it moves through the pipeline towards commercialization.
